Background In rural Germany, access to specialist care is limited due to low practice density and long waiting times. Telemedicine is increasingly used to bridge this gap. While teleconsultation’s effectiveness has been demonstrated, little is known about how primary care staff experience such interventions. The NeTKoH project (Neurological Teleconsultation with General Practitioners to strengthen specialist care in Western Pomerania, Germany) provided timely neurological expertise via teleconsultations between general practitioners (GPs), patients, and university clinic neurologists. This study explores the perceived benefits, challenges and suggestions for improvement from the perspective of GPs and medical assistants (MAs). Exploring the primary care perspective is essential for successfully implementing teleconsultations. Methods Using purposeful sampling, 13 GPs and 10 MAs participated in semi-structured interviews. Two interviews with MAs were excluded. Topics were developed through an inductive-deductive approach and analysed using focused thematic analysis following Kuckartz and Rädiker. Results Six main themes emerged: (1) Reflection on study participation (2) integration into everyday practice (3) neurological teleconsultation in practice (4) patient perspectives (5) technical aspects and (6) future implementation. Key benefits included improved access to specialist care, enhanced diagnostic confidence, timely therapeutic recommendations, and increased patient satisfaction. Teleconsultation was especially valued for uncertain neurological cases and for mobility-impaired or urgently in-need patients. Challenges included workflow integration, technical and spatial limitations. Suggested improvements included fixed consultation time slots, streamlined workflows and consistent neurologist assignment. Conclusions Neurological teleconsultation was perceived as valuable and feasible. Key challenges were GP participation and workflow integration. Successful routine implementation requires adequate technical infrastructure, fair reimbursement, and spatial feasibility. Findings indicate high acceptability among GPs and MAs and suggest telemedicine can strengthen outpatient care across other medical specialties.

BACKGROUND:Claims data are often used to investigate the quality of care for patients with low back pain (LBP). However, there is no standard regarding the preferred choice of ICD-10 codes for identifying patients with LBP, and guidelines for the treatment of LBP differ in their interpretation of ICD-10 codes. Furthermore, for some indicators measuring the quality of care, such as the appropriate use of imaging, it is necessary to differentiate between cases with specific, treatable causes and those without. This study therefore investigates coding practices for LBP in outpatient care and the use of imaging across specialist groups over a six-year period. METHODS:Based on the TREND cohort of the population-based Study of Health in Pomerania (SHIP), coding practices in claims data were analysed using data from 3,837 statutorily insured participants for the years 2014-2019. In total, eleven ICD-10 categories of relevance to LBP were included. We evaluated the findings based on two German guidelines: one for specific and one for non-specific LBP. RESULTS:At least one LBP diagnosis was coded for 2,474 participants (64%) during the entire observation period. The predominant ICD-10 category was M54 (dorsalgia, 87% of patients with LBP). Around half of the participants with M54 diagnoses also had diagnoses from other LBP-related categories in the same year. Diagnoses that can be assigned to specific LBP according to the respective German guideline occurred in 86% of patients with LBP. Participants who consulted only general practitioners during the observation period were more likely to receive only an M54 diagnosis and less likely to undergo imaging procedures. CONCLUSIONS:The results underline the high epidemiologic relevance of LBP. Using the German guideline on specific LBP as a reference, we categorized most LBP diagnoses as specific, contrary to common international assumptions. Most patients with LBP received multiple ICD-10 codes, complicating the distinction between non-specific and specific LBP based on claims data. Health care analyses on LBP require transparent reporting of the ICD codes used, along with a detailed discussion of the data's limitations.

Abstract Background Universal lipid screening in childhood for early detection and treatment of familial hypercholesterolemia is under discussion, but will also detect children with multifactorial dyslipidemia. Results from population-based studies can support the design of public health strategies. As few previous studies considered pubertal changes in serum lipid levels, we examined tracking of serum lipids from prepuberty to young adulthood in a population-based cohort. Methods This longitudinal study includes 692 children from the German Health Interview and Examination Survey for Children and Adolescents (KiGGS; baseline: 2003–2006, follow-up: 2014–2017) who were 6–8 years old at baseline, at least 18 years old at follow-up, and had measurements of serum total cholesterol (TC), high-density and non-high-density lipoprotein cholesterol (HDL-C; non-HDL-C) at both time points. We calculated proportions of participants by life stage-specific risk categories applying cut points for young children and young adults. We used correlation coefficients to estimate serum lipid tracking from childhood to young adulthood. The association between follow-up and baseline lipid levels was examined in sex-specific multivariable linear regression models including body mass index (BMI), health-related behaviors and medication use as covariables. Results The correlation coefficient between baseline and follow-up was 0.60 for non-HDL-C, 0.56 for TC, and 0.43 for HDL-C and was higher in males than in females. 67% of participants had acceptable and 9% had borderline/elevated non-HDL-C levels at both time points. Of participants with borderline/elevated non-HDL-C levels at baseline 32% remained in this category and 68% improved. Non-HDL-C levels at baseline explained 53% of the variance in levels at follow-up in males and 28% in females. After adjustment for covariables, the explained variance increased to 62% in males and 45% in females. An increase in BMI z-scores from childhood to young adulthood in all sexes and oral contraceptive use in females was positively associated with higher levels at follow-up. Conclusions Non-HDL-C levels in prepuberty are moderate predictors of levels in young adulthood, along with increasing BMI from childhood to young adulthood, and oral contraceptive use among women. Comprehensive strategies including public health interventions targeting elevated lipid levels and obesity in combination, are essential to prevent premature cardiovascular events.

BackgroundLow back pain (LBP) uses a large proportion of health care resources. Data are needed for health care planning, measuring adherence to guidelines for quality assurance, and assessing overuse and underuse of health care services. The aim of this review is to summarize claims data and describe trends in health care utilization for LBP for the years 2000 to 2020.MethodsThis scoping review summarizes studies and health reports using claims data of people aged ≥15 years covered by a statutory health insurance in Germany for the period 2000 to 2020. We searched publications in PubMed, EMBASE and Google. Data on health care services were extracted and trends over the years were summarized.ResultsWe included data from 76 publications, health reports and online databases. Every year, 25 to 32% of adults in Germany seek care for LBP. Most of the claims data cannot be pooled because of differences in standardization and reporting. However, trends are observable. Magnetic resonance imaging increased to 7.5%, plain radiography decreased to 15%. The number of sick leave days decreased slightly over time. Hospital admissions for LBP, spinal surgery, and opioid use increased. Outpatient rehabilitation increased, but the overall use of rehabilitation services remained relatively stable.ConclusionsInconsistent reporting standards and fragmentation of German claims data reporting, hinders a comprehensive understanding of health service utilization for low back pain. Despite limitations, current data suggest potential overuse of resources for LBP in Germany, consistently with international data. Given the high proportion of patients consulting for LBP better monitoring of health service utilization is needed to improve quality of care and resource allocation.

Abstract Background To date, colchicine and prednisolone are two effective therapies for the treatment of acute gout but have never been compared directly in a randomized clinical trial. In addition, in previous trials of treating acute gout patients with concomitant comorbidities were often excluded due to contraindications to naproxen. Study design This pragmatic, prospective, double-blind, double-dummy, parallel-group, randomized, non-inferiority trial compares prednisolone with colchicine in terms of non-inferiority in patients with acute gout. Patients presenting to their general practitioner with acute gout can be included if the gout attack has occurred within the last 2 days. A total of 60 practices in the vicinity of three university medical centers (Greifswald, Göttingen, and Würzburg) participate in the study. The intervention group receives 30 mg prednisolone for 5 days, while the group of standard care receives low-dose colchicine (day 1: 1.5 mg; days 2–5: 1 mg). The first dose of treatment is provided at day 0 when patients present to the general practitioner due to an acute gout attack. From day 0 to day 6, patients will be asked to complete a study diary on daily basis regarding pain quantification. For safety reasons, potential side effects and the course of systolic blood pressure are also assessed. Statistical analysis plan N = 314 patients have to be recruited to compensate for 10% of dropout and to allow for showing non-inferiority of prednisolone compared to colchicine with a power of 90%. We use permuted block randomization with block sizes of 2, 4, and 6 to avoid imbalanced treatment arms in this multi-center study; patients are randomized in a 1:1 ratio. The absolute level of pain on day 3 (in the last 24 h) is the primary outcome and measured on a numerical rating scale (NRS: 0–10). Using a multiple linear regression model adjusted for age, sex, and pain at baseline, prednisolone is considered non-inferior if the effect estimate including the confidence intervals is lower than a margin of 1 unit on the NRS. Average response to treatment, joint swelling and tenderness, physical function of the joint, and patients’ global assessment of treatment success are secondary outcomes. Discussion The trial will provide evidence from a direct comparison of colchicine and prednisolone regarding their efficacy of pain reduction in acute gout patients of primary care and to indicate possible safety signals. Trial registration ClinicalTrials.gov Identifier: NCT05698680 first posted on January 26, 2023 (retrospectively registered).

The role of glycosylated hemoglobin (HbA1c) in youth is largely unclear. The aims of this study are to investigate the distribution and potential determinants of HbA1c among a population-based sample of adolescents. The German Health Interview and Examination Survey for Children and Adolescents (KiGGS) Wave 2 includes a nationwide representative sample of 0-17-year-old participants. For this evaluation, data from a randomly selected subgroup aged 14-17 years and without diagnosed diabetes was included (n = 857). Percentile-based HbA1c values (measured at laboratory in whole blood samples by high performance liquid chromatography) were calculated to examine HbA1c distribution. Multivariable linear regression analyses were performed to investigate factors (age, sex, parental socioeconomic status, body mass index (BMI), birth weight, smoking, alcohol consumption, healthy food diversity, sport activity, oral contraceptive use) associated with HbA1c. The mean HbA1c level was 5.2% (minimum: 3.9%, P10: 4.8%, P50: 5.1%, P90: 5.5%, maximum: 6.7%). Overall, 2.8% of adolescents had an HbA1c value in the prediabetic range (5.7-6.4%) and 0.1% had an undiagnosed diabetes (≥6.5%). Multivariable regression analysis showed an inverse association of age with HbA1c (17 vs. 14 years: ß: -1.18; 95% CI -2.05, -0.31). Higher HbA1c values were observed for higher BMI-standard deviation scores (SDS) (ß: 0.24; 95% CI -0.04, 0.52) and smoking (ß: 0.73; 95% CI -0.12, 1.57), but these tendencies were non-significant. In sex-stratified analysis, smoking and birth weight were significantly associated with HbA1c in boys. Among adolescents without diagnosed diabetes in Germany, HbA1c values ranged from 3.9% to 6.7%. To ensure health in adulthood, the influence of determinants on HbA1c levels in younger age should be further investigated.

Truthmann, Julia PhD; Kasch, Richard MD; Hancock, Mark J. PhD; Maher, Christopher G. DMedSc; Chenot, Jean-François MD, MPH; Schmidt, Carsten Oliver PhD Author Information

Abstract Background Gout is the most common form of rheumatic disease in which monosodium urate crystals are deposited in the joints followed by acute inflammatory reactions. There are various approved drugs that can be prescribed for pain relief during an acute gout attack. However, to date, no direct comparison of efficacy of colchicine and prednisolone for the treatment of acute gout attacks has been investigated. Furthermore, the majority of previous research studies were not only conducted in tertiary centres but also excluded patients with common comorbidities due to contraindications to naproxen. Methods This pragmatic, prospective, double-blind, double-dummy, parallel-group, randomized, non-inferiority trial investigates whether prednisolone (intervention) is non-inferior to treatment with colchicine (active control) in patients with acute gout. Adult patients presenting with acute gout to their general practitioners in 60 practices across 3 university sites (Greifswald, Göttingen, and Würzburg) are eligible to participate in the study. Participants in the intervention group receive 30 mg prednisolone for 5 days. Those in the control group receive low-dose colchicine (day 1: 1.5 mg; days 2–5: 1 mg). The primary outcome is the absolute level of the most severe pain on day 3 (in the last 24 h) measured with an 11-item numerical rating scale. Day 0 is the day patients take their study medication for the first time. They are then asked to fill out a study diary the same time each day for pain quantification. Pain scores are used for comparison between the two medications. Secondary outcomes are average response to treatment, swelling, tenderness and physical function of the joint, patients’ global assessment of treatment success, use of additional pain medication and non-pharmacological pain therapies. For safety reasons, potential side effects and course of systolic blood pressure are assessed. Discussion This trial will provide evidence on the effectiveness of pain reduction and side effects of colchicine and prednisolone in acute gout in primary care. Trial registration ClinicalTrials.gov Identifier: NCT05698680 first posted on January 26, 2023 (retrospectively registered). URL of trial registry record: https://clinicaltrials.gov/study/NCT05698680

Zusammenfassung Ziel Gicht und Adipositas sind miteinander assoziiert und oft mit einem schlechten Gesundheitszustand verbunden. Es wird der aktuelle Stand der Diagnostik, Therapie und Prophylaxe der Gicht unter besonderer Berücksichtigung der Kontroversen dargestellt. Methodik Selektive Literatursuche und Zusammenfassung von Leitlinienempfehlungen. Ergebnisse Für den akuten Gichtanfall können unter Berücksichtigung von Komorbidität NSAR, Prednisolon oder Colchicin empfohlen werden. Für die Prophylaxe werden harnsäuresenkende Medikamente und Lebensstilmaßnahmen empfohlen. Schlussfolgerungen Die Evidenz für die Therapie und Prophylaxe der Gicht beruht auf nur wenigen Studien. Empfehlungen basieren oft vorwiegend auf empirischen Überlegungen. Für die Gicht und Adipositas werden ähnliche Lebensstilmaßnahmen empfohlen. Hier sind Public Health Ansätze sind vermutlich erfolgsversprechender als individualmedizinische Ansätze.

Die Unterscheidung zwischen „spezifischen“ und „nicht-spezifischen“ Rückenschmerzen ist oftmals schwierig und hat eine ziemlich große Grauzone. Ist eine aufwendige Diagnostik bei Rückenschmerzen also überhaupt gerechtfertigt? Und – falls ja: Führt diese dann auch zu einer besseren Versorgung? Das Autorenteam um Prof. Jean-François Chenot beleuchtet die Sinnhaftigkeit einer spezifischen Diagnosestellung und liefert so eine fundierte Grundlage für weitere Diskussionen.

Aims There is evidence for an increased type 2 diabetes (T2D) risk associated with depression, but its role for diabetes prevention remains unclear. This study aimed to add insight by investigating the impact of major depressive disorder (MDD) on prospective glycaemic changes. Methods The study was based on a cohort of n = 1,766 adults without diabetes (776 men, 990 women; 18-65 years of age) who participated in the mental health supplement of the German National Health Interview and Examination Survey (GNHIES98-MHS, 1997-1999) and in a follow-up survey (DEGS1, 2008-2011). Glycaemic status was defined as normoglycaemia [HbA1c < 39 mmol/mol (<5.7%)], prediabetes [39 <= HbA1c < 48 mmol/mol (5.7-6.4%)] and diabetes [HbA1c >= 48 mmol/mol (>= 6.5%), diagnosed diabetes, or antidiabetic medication], and glycaemic changes categorized as 'remission', 'stability' and 'progression'. Baseline MDD was assessed via a modified German version of the WHO Composite International Diagnostic Interview. Multivariable logistic regressions were applied to analyse the association of MDD with glycaemic changes and incident T2D, adjusting for socio-demographics, lifestyle conditions, chronic diseases, antidepressant use and mental health care. Results MDD prevalence was 21.4% for women and 8.9% for men. Among women, MDD was associated with a lower chance for remission (RRR 0.43; 95% CI 0.23, 0.82). Among men, MDD was not significantly related to glycaemic changes. MDD had no significant effect on incident T2D (men: OR 1.58; 0.55, 4.52; women: OR 0.76; 0.37, 1.58). Conclusions Findings of the current study highlight the role of depression in T2D prevention, particularly among women.

Study Design. Population-based cohort study. Objective. We examined associations between common lumbar degenerative changes observed on magnetic resonance imaging (MRI) and present or future low back pain (LBP). Summary of Background Data. The association between lumbar MRI degenerative findings and LBP is unclear. Longitudinal studies are sparse. Methods. Participants (n = 3369) from a population-based cohort study were imaged at study entry, with LBP status measured at baseline and 6-year follow-up. MRI scans were reported on for the presence of a range of MRI findings. LBP status was measured on a 0 to 10 scale. Regression models were used to estimate the cross-sectional and longitudinal associations between individual and multiple MRI findings and LBP severity. Separate longitudinal analyses were conducted for participants with and without baseline pain. Results. MRI findings were present in persons with and without back pain at baseline. Higher proportions were found in older age groups. 76.4% of participants had a least one MRI finding and 8.3% had five or more different MRI findings. Cross-sectionally, most MRI findings were slightly more common in those with LBP and pain severity was slightly higher in those with MRI findings (ranging from 0.06 for high intensity zone to 0.83 for spondylolisthesis). In the longitudinal analyses, we found most MRI findings were not associated with future LBP-severity regardless of the presence or absence of baseline pain. Compared to zero MRI findings, having multiple MRI findings (five or more) was associated with mildly greater pain-severity at baseline (0.84; 0.50-1.17) and greater increase in pain-severity over 6 years in those pain free at baseline (1.21; 0.04-2.37), but not in those with baseline pain (-0.30; -0.99 to 0.38). Conclusion. Our study shows that the MRI degenerative findings we examined, individually or in combination, do not have clinically important associations with LBP, with almost all effects less than one unit on a 0 to 10 pain scale.

(1) Background: Predicting chronic low back pain (LBP) is of clinical and economic interest as LBP leads to disabilities and health service utilization. This study aims to build a competitive and interpretable prediction model; (2) Methods: We used clinical and claims data of 3837 participants of a population-based cohort study to predict future LBP consultations (ICD-10: M40.XX-M54.XX). Best subset selection (BSS) was applied in repeated random samples of training data (75% of data); scoring rules were used to identify the best subset of predictors. The rediction accuracy of BSS was compared to randomforest and support vector machines (SVM) in the validation data (25% of data); (3) Results: The best subset comprised 16 out of 32 predictors. Previous occurrence of LBP increased the odds for future LBP consultations (odds ratio (OR) 6.91 [5.05; 9.45]), while concomitant diseases reduced the odds (1 vs. 0, OR: 0.74 [0.57; 0.98], >1 vs. 0: 0.37 [0.21; 0.67]). The area-under-curve (AUC) of BSS was acceptable (0.78 [0.74; 0.82]) and comparable with SVM (0.78 [0.74; 0.82]) and randomforest (0.79 [0.75; 0.83]); (4) Conclusions: Regarding prediction accuracy, BSS has been considered competitive with established machine-learning approaches. Nonetheless, considerable misclassification is inherent and further refinements are required to improve predictions.